Thomas Gavin D, Snetkov Vladimir A, Patel Rupal, Leach Richard M, Aaronson Philip I, Ward Jeremy P T
Department of Asthma, Allergy and Respiratory Science, GKT School of Medicine, King's College London, Guy's Campus, London SE1 9RT, UK.
Cardiovasc Res. 2005 Oct 1;68(1):56-64. doi: 10.1016/j.cardiores.2005.05.013.
Sphingosylphosphorylcholine (SPC) is an important lipid mediator that has been implicated in vascular disease. As it has not been studied in the pulmonary circulation, we examined its mechanisms of action in rat small intrapulmonary arteries (IPA).
IPA were mounted on a myograph for recording tension and intracellular Ca2+ concentration ([Ca2+]i). Ca2+ sensitisation was examined in alpha-toxin permeabilized IPA, and by Western blot analysis of MYPT1 phosphorylation.
SPC induced a slow but powerful vasoconstriction in IPA associated with an elevation in [Ca2+]i, with an EC50 for vasoconstriction of 12+/-2 microM. Removal of extracellular Ca2+ increased the EC50 to 76+/-33 microM (p<0.01) and abolished the rise in [Ca2+]i. Endothelial denudation or inhibition of NO synthase with L-NAME enhanced vasoconstriction. Treatment with pertussis toxin or the PLC inhibitor U731223 had no effect on SPC-induced vasoconstriction. The Rho kinase inhibitor Y27632 reduced SPC-induced vasoconstriction by approximately 70% and abolished both SPC-induced Ca2+ sensitisation in permeabilized IPA and the associated increase in MYPT1 phosphorylation; Ca2+ sensitisation was substantially inhibited by GDPbetaS. La3+ and 2-APB, at concentrations previously shown to block capacitative Ca2+ entry in IPA, suppressed SPC-induced vasoconstriction to the same extent as removal of extracellular Ca2+; residual tension was abolished by Y27632. Diltiazem was relatively ineffective. 2-APB also abolished the SPC-induced rise in [Ca2+]i. However, treatment with thapsigargin to empty intracellular stores had no effect on the elevation of [Ca2+]i induced by SPC.
We present evidence that SPC is a powerful vasoconstrictor of IPA and the novel finding that SPC-induced vasoconstriction in IPA is dependent on activation of a Ca2+ entry pathway with a similar sensitivity to La3+ and 2-APB as capacitative Ca2+ entry, although its activation is not dependent on emptying of PLC/IP3 or thapsigargin-sensitive intracellular stores.
鞘氨醇磷酸胆碱(SPC)是一种重要的脂质介质,与血管疾病有关。由于尚未在肺循环中进行研究,我们研究了其在大鼠肺内小动脉(IPA)中的作用机制。
将IPA安装在肌动描记器上记录张力和细胞内Ca2+浓度([Ca2+]i)。在α-毒素通透的IPA中检测Ca2+敏化,并通过蛋白质免疫印迹分析MYPT1磷酸化情况。
SPC在IPA中诱导缓慢但强烈的血管收缩,伴有[Ca2+]i升高,血管收缩的EC50为12±2μM。去除细胞外Ca2+使EC50增加到76±33μM(p<0.01),并消除了[Ca2+]i的升高。内皮剥脱或用L-NAME抑制一氧化氮合酶增强了血管收缩。用百日咳毒素或PLC抑制剂U731223处理对SPC诱导的血管收缩没有影响。Rho激酶抑制剂Y27632使SPC诱导的血管收缩降低约70%,并消除了SPC在通透的IPA中诱导的Ca2+敏化以及相关的MYPT1磷酸化增加;GDPβS可显著抑制Ca2+敏化。La3+和2-APB在先前显示可阻断IPA中容量性Ca2+内流的浓度下,与去除细胞外Ca2+一样程度地抑制了SPC诱导的血管收缩;Y27632消除了残余张力。地尔硫䓬相对无效。2-APB也消除了SPC诱导的[Ca2+]i升高。然而,用毒胡萝卜素排空细胞内储存对SPC诱导的[Ca2+]i升高没有影响。
我们提供证据表明SPC是IPA的一种强效血管收缩剂,并且有新发现表明SPC在IPA中诱导的血管收缩依赖于一种Ca2+内流途径的激活,该途径对La3+和2-APB的敏感性与容量性Ca2+内流相似,尽管其激活不依赖于PLC/IP3的排空或毒胡萝卜素敏感的细胞内储存。